Successful management of immune thrombocytopenic purpura with thalidomide in a patient with multiple myeloma [3]

Hematology Journal

Volumn 5, Issue 5, 2004, Pages 456-457

  Falco, Patrizia ^a   Bertola, Alessandra ^a   Bringhen, Sara ^a   Cavallo, Federica ^a   Boccadoro, Mario ^a   Palumbo, Antonio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INTERFERON; MELPHALAN; PREDNISONE; THALIDOMIDE;

ADULT; ANEMIA; CASE REPORT; DRUG RESPONSE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN BLOOD LEVEL; LETTER; MALE; MULTIPLE MYELOMA; RELAPSE; REMISSION; SENSORY NEUROPATHY; STEM CELL TRANSPLANTATION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG RESISTANCE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PLATELET TRANSFUSION; PREDNISONE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECURRENCE; THALIDOMIDE;

EID: 5444225627     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200404     Document Type: Letter

References (8)

1. Cines DB, Blanchette VS. Immune Thrombocytopenic Purpura. N Eng J Med 2002; 346: 995-1008.
2. McMillan R. Classical management of refractory adult immune (idiopathic) thrombocytopenic purpura. Blood Rev 2002; 16: 51.
3. Bussel JB. Novel approaches to refractory immune thrombocytopenic purpura. Blood Rev 2002; 16: 31-36.
4. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor á production by stimulated human monocytes. J Exp Med 1991; 173: 699-703.
5. Ossandon A, Cassara, EA, Priori R, Valesini G. Thalidomide: focus on its employment in rheumatologic diseases. Clin Exp Rheumatol 2002; 20: 709-718.
6. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N et al. Extended survival in advanced and refractory multiple myeloma after single agent thalidomide: identification of prognostic factors in a fase 2 study of 169 patients. Blood 2002; 98: 492-494.
7. Palumbo A, Giaccone L, Bertola A, Pregno P, Bringhen S, Rus C et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy in advanced myeloma. Haematologica 2001; 86: 399-403.
8. Giovanni B, Michelle E, Letizia C, Filippo B, Paolo PP, Giuseppe V et al. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled analysis of individual patient data from five studies. Leukemia Lymphoma 2002; 43: 2301-2307.